Emerging therapeutics in the management of COVID-19

Table 3 Cell and RNA-based therapies

Drug	Current use/FDA approval	Proposed mechanism of action	Published trials
Mesenchymal stem cells	FDA approved for graft versus host disease	Prevention of cytokine release as well as promotion of cellular repair/regeneration	(1) Leng et al[75]; and (2) See Clinicaltrials.gov for ongoing trials
MultiStem	Currently being studied for treatment of ischemic stroke, ulcerative colitis, acute myocardial infarction, and graft vs host disease	Immune system modulation, anti-inflammatory, pro-angiogenic	See Clinicaltrials.gov for ongoing trials
RNA based therapies	Have been utilized as anticancer and antiviral therapy. Have also been implemented in genetic diseases	Interfere with gene expression through RNA interference	See Clinicaltrials.gov for ongoing trials

FDA: Federal Drug Administration.